Ngā hua rapu - Aaron N. Hata
- E whakaatu ana i te 1 - 20 hua o te 60
- Haere ki te Whārangi Whai Ake
-
1
Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights mā Catherine B. Meador, Aaron N. Hata
I whakaputaina 2020Revisão -
2
-
3
-
4
-
5
-
6
-
7
Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies mā Clemens Grassberger, David M. McClatchy, Changran Geng, Sophia C. Kamran, Florian J. Fintelmann, Yosef E. Maruvka, Zofia Piotrowska, Henning Willers, Lecia V. Sequist, Aaron N. Hata, Harald Paganetti
I whakaputaina 2019Artigo -
8
Unprocessed genomic uracil as a source of DNA replication stress in cancer cells mā Sneha Saxena, Christopher S. Nabel, Turner W. Seay, Parasvi S. Patel, Ajinkya S. Kawale, Caroline R. Crosby, Helene Tigro, Eugene Oh, Matthew G. Vander Heiden, Aaron N. Hata, Zucai Suo, Lee Zou
I whakaputaina 2024Artigo -
9
Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases mā Hironori Uruga, Emine Bozkurtlar, Tiffany G. Huynh, Alona Muzikansky, Yasushi Goto, María Gomez‐Caraballo, Aaron N. Hata, Justin F. Gainor, Eugene J. Mark, Jeffrey A. Engelman, Michael Lanuti, Mari Mino‐Kenudson
I whakaputaina 2016Artigo -
10
Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction mā Kyle Vaccaro, Juliet Allen, Troy W. Whitfield, Asaf Maoz, Sarah Reeves, José Velarde, Dian Yang, Anna Meglan, Juliano Ribeiro, Jasmine Blandin, Nicole Phan, George W. Bell, Aaron N. Hata, Kipp Weiskopf
I whakaputaina 2024Artigo -
11
Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity mā Lynnette Marcar, Kankana Bardhan, Liliana Gheorghiu, Patrick Dinkelborg, Heike N. Pfäffle, Qi Liu, Meng Wang, Zofia Piotrowska, Lecia V. Sequist, Kerstin Borgmann, Jeffrey Settleman, Jeffrey A. Engelman, Aaron N. Hata, Henning Willers
I whakaputaina 2019Artigo -
12
Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers mā Aaron N. Hata, Alan T. Yeo, Anthony C. Faber, Eugene Lifshits, Zhao Chen, Katherine A. Cheng, Zandra E. Walton, Kristopher A. Sarosiek, Anthony Letai, Rebecca S. Heist, Mari Mino‐Kenudson, Kwok‐Kin Wong, Jeffrey A. Engelman
I whakaputaina 2014Artigo -
13
Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment mā Tiffany G. Huynh, Vicente Morales‐Oyarvide, Meghan Campo, Justin F. Gainor, Emine Bozkurtlar, Hironori Uruga, Ling Zhao, María Gomez‐Caraballo, Aaron N. Hata, Eugene J. Mark, Michael Lanuti, Jeffrey A. Engelman, Mari Mino‐Kenudson
I whakaputaina 2016Artigo -
14
Treatment with Next-Generation ALK Inhibitors Fuels Plasma <i>ALK</i> Mutation Diversity mā Ibiayi Dagogo‐Jack, Marguerite Rooney, W. Marston Linehan, Rebecca J. Nagy, Beow Y. Yeap, Harper Hubbeling, Emily Chin, Jennifer Ackil, Anna F. Farago, Aaron N. Hata, Jochen K. Lennerz, Justin F. Gainor, Richard B. Lanman, Alice T. Shaw
I whakaputaina 2019Artigo -
15
MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC mā Naoki Haratake, Hiroki Ozawa, Yoshihiro Morimoto, Nami Yamashita, Tatsuaki Daimon, Atrayee Bhattacharya, Keyi Wang, Ayako Nakashoji, Hideko Isozaki, Mototsugu Shimokawa, Chie Kikutake, Mikita Suyama, Asato Hashinokuchi, Kazuki Takada, Tomoyoshi Takenaka, Tomoharu Yoshizumi, Tetsuya Mitsudomi, Aaron N. Hata, Donald Küfe
I whakaputaina 2023Artigo -
16
A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor mā Ibiayi Dagogo‐Jack, Philicia Moonsamy, Justin F. Gainor, Jochen K. Lennerz, Zofia Piotrowska, W. Marston Linehan, Inga T. Lennes, Lecia V. Sequist, Alice T. Shaw, Kelly Goodwin, Sara E. Stevens, Andrew Do, Subba R. Digumarthy, Kristin S. Price, Alona Muzikansky, Aaron N. Hata, Rebecca S. Heist
I whakaputaina 2021Artigo -
17
TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in <i>BRAF-</i> Mutant Melanoma mā Ryan B. Corcoran, S. Michael Rothenberg, Aaron N. Hata, Anthony C. Faber, Adriano Piris, Rosalynn M. Nazarian, Ronald D. Brown, Jason T. Godfrey, Daniel Winokur, John R. Walsh, Mari Mino‐Kenudson, Shyamala Maheswaran, Jeffrey Settleman, Jennifer A. Wargo, Keith T. Flaherty, Daniel A. Haber, Jeffrey A. Engelman
I whakaputaina 2013Artigo -
18
Targeting TREX1 induces innate immune response in drug-resistant Small Cell Lung Cancer mā Takahiko Murayama, Navin R. Mahadevan, Catherine B. Meador, Elena Ivanova, Yuqiao Pan, Erik H. Knelson, Tetsuo Tani, Jun Nakayama, Xueying Ma, Tran C. Thai, Yin P. Hung, William Kim, Hideo Watanabe, Kathy Q. Cai, Aaron N. Hata, Cloud P. Paweletz, David A. Barbie, Israel Cañadas
I whakaputaina 2024Artigo -
19
Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells mā Moiez Ali, Min Lu, Hazel X. Ang, Ryan S. Soderquist, Christine E. Eyler, Haley M. Hutchinson, Carolyn Glass, Christopher F. Bassil, Omar Lopez, D. Lucas Kerr, Christina J. Falcon, Helena A. Yu, Aaron N. Hata, Collin M. Blakely, Caroline E. McCoach, Trever G. Bivona, Kris C. Wood
I whakaputaina 2022Artigo -
20
Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in <i>ROS1</i>-Positive Non–Small-Cell Lung Cancer mā Justin F. Gainor, Diane Tseng, Satoshi Yoda, Ibiayi Dagogo‐Jack, Luc Friboulet, W. Marston Linehan, Harper Hubbeling, Leila Dardaei, Anna F. Farago, Katherine R. Schultz, Lorin A. Ferris, Zofia Piotrowska, James C.H. Hardwick, Donghui Huang, Mari Mino‐Kenudson, A. John Iafrate, Aaron N. Hata, Beow Y. Yeap, Alice T. Shaw
I whakaputaina 2017Artigo
Ngā utauta rapu:
Ngā marau whai pānga
Cancer research
Biology
Medicine
Cancer
Internal medicine
Genetics
Gene
Lung cancer
Oncology
Biochemistry
Mutant
Cell biology
KRAS
Pathology
Colorectal cancer
Malignant pleural effusion
Apoptosis
Crizotinib
Immunology
Mutation
Receptor
Adenocarcinoma
Epidermal growth factor receptor
Pharmacology
Targeted therapy
Anaplastic lymphoma kinase
Chemistry
Gene expression
Signal transduction
ALK inhibitor